链球菌中毒性休克综合征对静脉-动脉体外膜氧合无效时序贯体外病原清除与细胞导向体外治疗:一例病例报告
本文为病例报告,描述一名28岁女性剖宫产术后5天发生链球菌中毒性休克综合征(STSS),表现为呼吸窘迫、低血压和多器官衰竭。在插管、抗生素、血管升压药和液体复苏等常规治疗下病情仍恶化,遂行静脉-动脉体外膜氧合(VA-ECMO),随后启动Seraph 100血液滤器进行病原血液灌流,再以选择性细胞分离装置(SCD)进行免疫调节。未观察到装置相关不良事件;血管升压药在4天后停用,ECMO在6天后撤机,7天后出现肾脏恢复迹象,14天后拔管,13天后转为常规血液透析,11天后停止所有肾脏替代治疗。作者认为该多模式体外支持策略对最顽固的重症病例是一种有前景的治疗策略,并指出需进一步研究评估其安全性和有效性。
要点
- 28岁女性剖宫产术后5天发生STSS,经常规插管、抗生素、血管升压药和液体复苏后病情仍恶化,遂行VA-ECMO。
- 在VA-ECMO基础上序贯启动Seraph 100血液灌流进行病原清除,随后以选择性细胞分离装置(SCD)进行免疫调节。
- 未观察到装置相关不良事件;血管升压药4天后停用,ECMO 6天后撤机,7天后出现肾脏恢复迹象,14天后拔管。
- 13天后转为常规血液透析,11天后停止所有肾脏替代治疗。
- 作者认为该序贯多模式体外支持策略对最顽固的重症病例是有前景的治疗策略,并指出需进一步研究评估其安全性和有效性。
适用人群与场景
- 剖宫产术后5天发生链球菌中毒性休克综合征(STSS)的28岁女性,表现为呼吸窘迫、低血压和多器官衰竭,经常规插管、抗生素、血管升压药和液体复苏后病情仍恶化。
处置流程与药物剂量
- 常规治疗包括插管、抗生素、血管升压药和液体复苏,但病情仍恶化后行静脉-动脉体外膜氧合(VA-ECMO)。
- VA-ECMO启动后,使用Seraph 100血液滤器进行病原血液灌流,随后以选择性细胞分离装置(SCD)进行免疫调节。
研究设计与关键结果
- 病例报告:28岁女性剖宫产术后5天发生STSS伴呼吸窘迫、低血压和多器官衰竭,常规治疗恶化后行VA-ECMO,序贯Seraph 100血液灌流和SCD免疫调节。
- 未观察到装置相关不良事件;血管升压药4天后停用,ECMO 6天后撤机,7天后出现肾脏恢复迹象,14天后拔管。
- 13天后转为常规血液透析,11天后停止所有肾脏替代治疗。
- 作者称这是首次报道VA-ECMO、Seraph 100血液灌流与SCD细胞导向免疫调节联合使用。
证据类型、等级与局限
- 证据类型:病例报告。
- 局限:作者指出需进一步研究评估该序贯方案的安全性和有效性。
对床旁实践的改变
- 作者认为,这种多模式体外支持策略对最顽固的重症病例是一种有前景的治疗策略。
- 作者指出,需进一步研究评估该序贯方案的安全性和有效性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Streptococcal toxic shock syndrome (STSS) is a fulminant complication of predominantly invasive group A streptococcal infections. STSS is often characterized by influenza-like symptoms, including fever, chills, and myalgia that can quickly progress to sepsis with hypotension, tachycardia, tachypnea, and multiple organ failure (kidney, liver, lung, or blood). Mortality can exceed 50% depending on the severity of symptoms.
CASE SUMMARY: Here, we describe a novel, multi-extracorporeal intervention strategy in a case of severe septic shock secondary to STSS. A 28-year-old woman 5 days after cesarean section developed STSS with respiratory distress, hypotension, and multiple organ failure. Despite conventional therapy with intubation, antibiotics, vasopressors, and fluid resuscitation, her condition worsened. She was placed on venoarterial extracorporeal membrane oxygenation (VA-ECMO) with subsequent initiation of pathogen hemoperfusion using the Seraph 100 blood filter, followed by immunomodulation with the selective cytopheretic device (SCD). No device-related adverse events were observed. The patient's condition gradually stabilized with discontinuation of vasopressors after 4 days, ECMO decannulation after 6 days, evidence of renal recovery after 7 days, and extubation from mechanical ventilation after 14 days. She was transferred to conventional hemodialysis after 13 days and discontinued all kidney replacement therapy 11 days later.
CONCLUSIONS: This is the first reported use of VA-ECMO, Seraph 100 hemoperfusion, and cell-directed immunomodulation with SCD. This multimodal approach to extracorporeal support represents a promising therapeutic strategy for the most refractory critical care cases. Further studies are needed to assess the safety and efficacy of this sequential approach.
参考来源
- Amerson SJ, Hoffman M, Abouzahr F, et al. Sequential Extracorporeal Therapy of Pathogen Removal Followed by Cell-Directed Extracorporeal Therapy in Streptococcal Toxic Shock Syndrome Refractory to Venoarterial Extracorporeal Membrane Oxygenation: A Case Report. Crit Care Explor. 2024. PMID: 38415021. doi:10.1097/CCE.0000000000001058
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。